| Dissecting hematopoietic and renal cell heterogeneity in adult zebrafish at single-cell resolution using RNA sequencing Q Tang, S Iyer, R Lobbardi, JC Moore, H Chen, C Lareau, C Hebert, ... Journal of Experimental Medicine 214 (10), 2875-2887, 2017 | 152 | 2017 |
| Glycogen synthase kinase 3 inhibitors induce the canonical WNT/β-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma EY Chen, MT DeRan, MS Ignatius, KB Grandinetti, R Clagg, KM McCarthy, ... Proceedings of the National Academy of Sciences 111 (14), 5349-5354, 2014 | 143 | 2014 |
| Optimized cell transplantation using adult rag2 mutant zebrafish Q Tang, NS Abdelfattah, JS Blackburn, JC Moore, SA Martinez, FE Moore, ... Nature methods 11 (8), 821-824, 2014 | 134 | 2014 |
| Clonal evolution enhances leukemia-propagating cell frequency in T cell acute lymphoblastic leukemia through Akt/mTORC1 pathway activation JS Blackburn, S Liu, JL Wilder, KP Dobrinski, R Lobbardi, FE Moore, ... Cancer cell 25 (3), 366-378, 2014 | 124 | 2014 |
| Single-cell imaging of normal and malignant cell engraftment into optically clear prkdc-null SCID zebrafish JC Moore, Q Tang, NT Yordán, FE Moore, EG Garcia, R Lobbardi, ... Journal of Experimental Medicine 213 (12), 2575-2589, 2016 | 71 | 2016 |
| Single-cell transcriptional analysis of normal, aberrant, and malignant hematopoiesis in zebrafish FE Moore, EG Garcia, R Lobbardi, E Jain, Q Tang, JC Moore, M Cortes, ... Journal of Experimental Medicine 213 (6), 979-992, 2016 | 69 | 2016 |
| Identification and characterization of T reg–like cells in zebrafish M Kasheta, CA Painter, FE Moore, R Lobbardi, A Bryll, E Freiman, ... Journal of Experimental Medicine 214 (12), 3519-3530, 2017 | 68 | 2017 |
| The NOTCH1/SNAIL1/MEF2C pathway regulates growth and self-renewal in embryonal rhabdomyosarcoma MS Ignatius, MN Hayes, R Lobbardi, EY Chen, KM McCarthy, P Sreenivas, ... Cell reports 19 (11), 2304-2318, 2017 | 63 | 2017 |
| TOX regulates growth, DNA repair, and genomic instability in T-cell acute lymphoblastic leukemia R Lobbardi, J Pinder, B Martinez-Pastor, M Theodorou, JS Blackburn, ... Cancer discovery 7 (11), 1336-1353, 2017 | 57 | 2017 |
| T cell immune deficiency in zap70 mutant zebrafish JC Moore, TS Mulligan, NT Yordán, D Castranova, VN Pham, Q Tang, ... Molecular and cellular biology, 2016 | 42 | 2016 |
| Fine-tuning of Hh signaling by the RNA-binding protein Quaking to control muscle development R Lobbardi, G Lambert, J Zhao, R Geisler, HR Kim, FM Rosa Development 138 (9), 1783-1794, 2011 | 34 | 2011 |
| JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia MR Mansour, S He, Z Li, R Lobbardi, BJ Abraham, C Hug, S Rahman, ... Journal of Experimental Medicine 215 (7), 1929-1945, 2018 | 26 | 2018 |
| Quaking RNA-binding proteins control early myofibril formation by modulating tropomyosin A Bonnet, G Lambert, S Ernest, FX Dutrieux, F Coulpier, S Lemoine, ... Developmental cell 42 (5), 527-541. e4, 2017 | 20 | 2017 |
| Development of a selective CDK2-E inhibitor in CCNE driven cancers YJ Choi, S Wenglowsky, V Brown, N Bifulco, YS Choi, J Guo, M Hatlen, ... Cancer research 81 (13_Supplement), 1279-1279, 2021 | 6 | 2021 |
| BLU-222, an investigational, potent, and selective CDK2 inhibitor, demonstrated robust antitumor activity in CCNE1-amplified ovarian cancer models [abstract, unpublished] V Brown, N House, R Vargas, J Guo, R Wang, R Lobbardi Proceedings of the American Association for Cancer Research Annual Meeting …, 2022 | 5 | 2022 |
| Evaluation of PRKACA as a therapeutic target for fibrolamellar carcinoma SS Schalm, E O’Hearn, K Wilson, TP LaBranche, G Silva, Z Zhang, ... bioRxiv, 2022.01. 31.477690, 2022 | 4 | 2022 |
| Efficient transduction of zebrafish melanoma cell lines and embryos using lentiviral vectors M Fazio, S Avagyan, E Van Rooijen, W Mannherz, CK Kaufman, ... Zebrafish 14 (4), 379-382, 2017 | 4 | 2017 |
| A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination with trametinib, in … M McKean, AI Spira, E Rosen, V Subbiah, V Moreno, V Gambardella, ... Journal of Clinical Oncology 41 (16_suppl), TPS3163-TPS3163, 2023 | 2 | 2023 |
| CFT7455, a Novel IKZF1/3 Degrader, Demonstrates Potent Anti-Tumor Activity in Models of Non-Hodgkin's Lymphoma As a Single Agent or in Combination with Clinically Approved Agents S Perino, RJ Kirby, R Agafonov, P Chaturvedi, S Eron, A Good, A Hart, ... Blood 140 (Supplement 1), 11575-11575, 2022 | 1 | 2022 |
| A clinical update on BLU-782, an investigational ALK2 inhibitor in development for fibrodysplasia ossificans progressiva (FOP) A Davis, F Albayya, R Lobbardi, M Palmer, CA Sherwin, S Green, ... | 1 | 2019 |
